KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Operating Expenses (2016 - 2026)

Neogenomics filings provide 17 years of Operating Expenses readings, the most recent being $99.1 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 1.95% to $99.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $428.2 million, a 10.58% increase, with the full-year FY2025 number at $430.2 million, up 12.55% from a year prior.
  • Operating Expenses hit $99.1 million in Q1 2026 for Neogenomics, up from $96.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $124.9 million in Q2 2025 to a low of $83.2 million in Q4 2022.
  • Median Operating Expenses over the past 5 years was $94.4 million (2024), compared with a mean of $94.7 million.
  • The widest YoY moves for Operating Expenses: up 59.24% in 2022, down 4.16% in 2022.
  • Neogenomics' Operating Expenses stood at $83.2 million in 2022, then grew by 3.55% to $86.2 million in 2023, then rose by 11.02% to $95.7 million in 2024, then grew by 1.15% to $96.8 million in 2025, then grew by 2.43% to $99.1 million in 2026.
  • The last three reported values for Operating Expenses were $99.1 million (Q1 2026), $96.8 million (Q4 2025), and $107.5 million (Q3 2025) per Business Quant data.